Oops, it looks like this browser is no longer supported or has retired. For the best Chivas.com experience we recommend upgrading to Microsoft Edge.

Try the Edge Browser
Registrate al newsletter de Chivas
$595 Total funding received


Using just refrigerator magnets and laser pointers, we are revolutionising global health diagnostics by developing purely mechanical, handheld, reusable devices capable of detecting multiple diseases by analysing a single drop of blood in a disposable cuvette. Our flagship product, the Rapid Assessment of Malaria (RAM), is 50 times faster, a tenth of the cost, and able to detect levels of infection 100 times smaller than current diagnostic methods. We are focusing on providing point-of-care solutions that can detect these infectious diseases at an early stage – even before symptoms arise - because early detection is the only way to eliminate expensive treatment costs, save lives, and achieve eradication. As we continue to build out the platform to include other high-impact diseases such as dengue fever, tuberculosis, zika, and typhoid, we will simultaneously leverage our devices’s electronics to create a full patient identification system to help organisations track outbreaks and manage resources more efficiently.


Despite being 100% curable, malaria affects half of the world’s population, kills one million people annually, and costs $12 billion a year to control in Africa alone, because only one out of eight infections are properly diagnosed. The lack of early diagnosis is the leading cause of serious illness because without simple and accurate diagnostic methods, medication cannot be distributed due to fear of resistance, cost, and potential side effects, and untreated individuals continue to transmit the disease. Our patented device solves these problems by exploiting a magnetic biomarker produced by malaria parasites to provide a quantitative diagnosis in less than a minute, from a finger prick. We make elimination possible by providing a device that can detect asymptomatic infections at the point of care, and, at a cost of only $0.25/test, save organisations $100,000 over the lifetime of the device, allowing resources to be redirected to address other needs.